抗体受託製造の市場規模、シェア、動向分析レポート：製品別、由来別、最終用途別、地域別、セグメント予測、2025年～2030年

抗体受託製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗体受託製造の市場規模は2025年から2030年にかけて10.1%のCAGRを記録し、2030年までに317億6,000万米ドルに達すると予測されています。

治療用抗体の生産需要の増加が、予測期間中の市場成長を促進する主な要因です。抗体は、異常な細胞を正確に標的とする主要なバイオ医薬品です。そのため、多くのバイオ医薬品企業が、がん、関節炎、リウマチ性心疾患などの慢性疾患の治療用として、先進的な抗体の開発に力を入れ始めています。COVID-19の影響は、COVID-19患者の治療として使用されるモノクローナル抗体療法の適用により、市場の成長を後押ししています。

主要企業による抗体製造のための研究開発予算の急増も市場の成長を後押ししています。現在進行中のCOVID-19との闘いでは、モノクローナル抗体（mAb）療法が効果的な治療法であることが証明されています。この治療の目的は、入院を予防し、ウイルス量を減少させ、症状の重症度を最小限に抑えることです。

コロナウイルスが大流行した際も、バイオ医薬品企業のサプライチェーンは堅調を維持し、世界中でほとんど影響を受けなかった。同様に、抗体受託製造業者も、COVID-19ワクチンや治療薬に関連する治療に使用される抗体の製造需要の増加を観察しています。このように、抗体受託製造市場には将来的に多くのビジネスチャンスがあります。例えば、2021年12月、Samsung BiologicsとAstraZenecaの間で、COVID-19の潜在的治療のために開発中のバイナリー抗体の合併であるEvusheldを製造する契約が結ばれました。

CMOの成長は、バイオ医薬品業界が提供する好機に大きく左右されます。ライフサイエンス分野へのベンチャーキャピタル投資の拡大と堅調化は、市場を牽引すると予想される2つの重要な機会です。例えば、2022年にFUJIFILM Diosynth Biotechnologiesはノースカロライナ州での事業拡大を発表しました。この事業拡大により、同社は2024年までに研究者や科学者を含む熟練したポジションを増やし、強力な商業プロセスを生み出す予定です。

抗体受託製造市場レポートハイライト

• モノクローナル抗体をベースとする抗体受託製造は、生物製剤開発のための哺乳類発現系の高い浸透により、2024年に約76.42%の最大市場シェアを獲得しました。
• この市場で提供されるソースに基づくと、哺乳動物セグメントは、より信頼性が高く、堅牢で、比較的成熟した技術と考えられているため、2024年に57.52％の最大シェアに貢献しました。
• アジア太平洋地域は、インド、韓国、中国などの新興経済諸国が競争を維持するために開発を取り入れているため、予測期間中に最も急成長する地域市場になると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗体受託製造市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 業界の課題
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19分析

第4章 抗体受託製造市場：製品の推定・動向分析

• セグメントダッシュボード
• 製品の変動分析
• 製品別、2018年-2030年
• モノクローナル抗体
• ポリクローナル抗体
• その他

第5章 由来のビジネス分析

• セグメントダッシュボード
• 由来変動分析
• 由来別、2018年-2030年
• 哺乳類由来
• 微生物

第6章 最終用途のビジネス分析

• セグメントダッシュボード
• 最終用途変動分析
• 最終用途別、2018年-2030年
• バイオ医薬品企業
• 研究ラボ
• その他

第7章 抗体受託製造市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • クウェート

第8章 競合情勢

• 参入企業
• 戦略マッピング
• 企業市況分析、2024年（企業ヒートマップ分析）
• 企業プロファイル
  • Lonza
  • Samsung Biologics
  • WuXi Biologics
  • Charles River Laboratories
  • FUJIFILM Holdings Corporation
  • Boehringer Ingelheim GmbH
  • AGC Biologics
  • Cytovance Biologics, Inc.
  • EMERGENT
  • Thermo Fisher Scientific, Inc.
  • Catalent, Inc
  • Laboratory Corporation of America Holdings

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 4 Global Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 5 Global Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 6 Global Antibody Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
• Table 7 U.S. Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 8 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 9 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 10 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 11 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 12 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 13 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 14 U.S. Canada Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 15 Canada Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 16 Canada Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 17 Mexico Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 18 Mexico Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 19 Mexico Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 20 Europe Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 21 Europe Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 22 Europe Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 23 Europe Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 24 Germany Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 25 Germany Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 26 Germany Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 27 UK Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 28 UK Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 29 UK Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 30 France Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 31 France Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 32 France Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 33 Italy Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 34 Italy Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 35 Italy Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 36 Spain Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 37 Spain Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 38 Spain Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 39 Denmark Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 40 Denmark Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 41 Denmark Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 42 Sweden Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 43 Sweden Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 44 Sweden Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 45 Norway Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 46 Norway Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 47 Norway Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 52 China Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 53 China Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 54 China Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 55 Japan Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 56 Japan Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 57 Japan Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 58 India Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 59 India Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 60 India Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 61 South Korea Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 62 South Korea Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 63 South Korea Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 64 Australia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 65 Australia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 66 Australia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 67 Thailand Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 68 Thailand Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 69 Thailand Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 70 Latin America Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 71 Latin America Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 72 Latin America Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 73 Latin America Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 74 Latin America Antibody Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 75 Brazil Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 76 Brazil Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 77 Brazil Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 78 Argentina Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 79 Argentina Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 80 Argentina Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 85 South Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 86 South Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 87 South Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 90 Saudi Arabia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 91 UAE Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 92 UAE Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 93 UAE Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Table 94 UAE Antibody Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 95 Kuwait Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 96 Kuwait Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
• Table 97 Kuwait Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Antibody Contract Manufacturing, Market Segmentation
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Market Dynamics
• Fig. 8 Market Driver Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 PESTEL Analysis, By SWOT Analysis
• Fig. 12 Regional Marketplace: Key Takeaways
• Fig. 13 Global Antibody Contract Manufacturing, for Monoclonal Antibodies, 2018 - 2030 (USD Million)
• Fig. 14 Global Antibody Contract Manufacturing, for Polyclonal Antibodies, 2018 - 2030 (USD Million)
• Fig. 15 Global Antibody Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
• Fig. 16 Global Antibody Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
• Fig. 17 Global Antibody Contract Manufacturing, for Microbial, 2018 - 2030 (USD Million)
• Fig. 18 Global Antibody Contract Manufacturing, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
• Fig. 19 Global Antibody Contract Manufacturing, for Research Laboratories, 2018 - 2030 (USD Million)
• Fig. 20 Global Antibody Contract Manufacturing, for others, 2018 - 2030 (USD Million)
• Fig. 21 Regional Outlook, 2024 & 2030
• Fig. 22 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 23 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 27 UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 29 France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 36 India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 37 China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 39 South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Colombia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Middle East & Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 47 South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Antibodies Contract Manufacturing Market Growth & Trends:

The global antibody contract manufacturing market size is expected to reach USD 31.76 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Report Highlights:

• Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 76.42% in 2024, owing to the high penetration of mammalian expression systems for biologics development
• Based on the source offered in this market, the mammalian segment contributed the largest share of 57.52% in 2024, as they are considered a more reliable, robust, and relatively mature technology
• Asia Pacific is expected to emerge as the fastest-growing regional market during forecast period, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Contract Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
  • 3.2.2. Market Restraints Analysis
  • 3.2.3. Industry Challenges
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Analysis

Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Product Movement Analysis
• 4.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
• 4.4. Monoclonal Antibodies
  • 4.4.1. Monoclonal Antibodies Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
• 4.5. Polyclonal Antibodies
  • 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

• 5.1. Segment Dashboard
• 5.2. Source Movement Analysis
• 5.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
• 5.4. Mammalian Source
  • 5.4.1. Mammalian Source Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Microbial
  • 5.5.1. Microbial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. Segment Dashboard
• 6.2. End Use Movement Analysis
• 6.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
• 6.4. Biopharmaceutical Companies
  • 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Research Laboratories
  • 6.5.1. Research Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional market share analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Landscape
    • 7.3.2.4. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Landscape
    • 7.3.3.4. Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Landscape
    • 7.3.4.4. Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Landscape
    • 7.4.2.4. UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Landscape
    • 7.4.3.4. Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Landscape
    • 7.4.4.4. France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Landscape
    • 7.4.5.4. Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Landscape
    • 7.4.6.4. Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Landscape
    • 7.4.7.4. Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Landscape
    • 7.4.8.4. Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Landscape
    • 7.4.9.4. Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Landscape
    • 7.5.2.4. China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Landscape
    • 7.5.3.4. Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Landscape
    • 7.5.4.4. India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Landscape
    • 7.5.5.4. South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Landscape
    • 7.5.6.4. Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Landscape
    • 7.5.7.4. Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Landscape
    • 7.6.2.4. Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Landscape
    • 7.6.3.4. Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Landscape
    • 7.7.2.4. Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Landscape
    • 7.7.3.4. UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. South Africa
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Landscape
    • 7.7.4.4. South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Landscape
    • 7.7.5.4. Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
• 8.4. Company Profiles
  • 8.4.1. Lonza
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Service Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Samsung Biologics
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Service Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. WuXi Biologics
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Service Benchmarking
  • 8.4.4. Charles River Laboratories
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Service Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. FUJIFILM Holdings Corporation
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Service Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Boehringer Ingelheim GmbH
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Service Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. AGC Biologics
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Service Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Cytovance Biologics, Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Service Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. EMERGENT
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Service Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Thermo Fisher Scientific, Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Service Benchmarking
    • 8.4.10.4. Strategic Initiatives
    • 8.4.10.5. Strategic Initiatives
  • 8.4.11. Catalent, Inc
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Service Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. Laboratory Corporation of America Holdings
    • 8.4.12.1. Participant's Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Service Benchmarking
    • 8.4.12.4. Strategic Initiatives